SCHEMBL4874399

SCHEMBL4874399

CSc1cccc(Nc2ncc(F)cc2C(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.49
KMT2A Q03164 7/20 0.49
MAPK1 P28482 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MAPT P10636 2/20 0.49
TP53 P04637 1/20 0.49
POLB P06746 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ABCG2 Q9UNQ0 3/20 0.46
ABCC1 P33527 1/20 0.46
CYP1A2 P05177 4/20 0.44
CYP2C9 P11712 3/20 0.44
PKM P14618 2/20 0.44
HTT P42858 2/20 0.44
DHODH Q02127 2/20 0.44
LMNA P02545 2/20 0.44
CYP3A4 P08684 2/20 0.44
ALDH1A1 P00352 2/20 0.44
GMNN O75496 1/20 0.44
TTR P02766 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15635777 0.84 LMNA (0.58) MEN1KMT2AMAPK1ABCG2CYP1A2
SCHEMBL15636037 0.83 DHODH (0.58) MEN1KMT2ASMN1; SMN2MAPTCYP1A2
SCHEMBL4880785 0.82 MAPT (0.51) MEN1KMT2AMAPK1SMN1; SMN2MAPT
SCHEMBL4880802 0.82 MAPT (0.51) MEN1KMT2AMAPK1SMN1; SMN2MAPT
SCHEMBL17110905 0.81 AKR1C3 (0.55) MEN1KMT2AMAPK1SMN1; SMN2MAPT
SCHEMBL870223 0.81 DHODH (0.53) MEN1KMT2ACYP1A2CYP2C9PKM
SCHEMBL869587 0.81 DHODH (0.46) MEN1KMT2AMAPK1MAPTABCG2
SCHEMBL5256676 0.81 MEN1 (0.65) MEN1KMT2AMAPK1SMN1; SMN2MAPT
SCHEMBL17110898 0.81 MEN1 (0.68) MEN1KMT2AMAPK1MAPTPOLB
SCHEMBL4775826 0.80 PDE5A (0.53) MEN1KMT2AMAPK1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases ASTRAZENECA AB (SE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases PDE4A, PDE4B, PDE5A MEN1 3231/4885KMT2A 1222/4885MAPK1 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.